News
NUVL
63.06
-1.85%
-1.19
Nuvalent Price Target Announced at $97.00/Share by Jefferies
Dow Jones · 1d ago
Nuvalent Initiated at Buy by Jefferies
Dow Jones · 1d ago
Jefferies Initiates Coverage On Nuvalent with Buy Rating, Announces Price Target of $97
Benzinga · 1d ago
NUVALENT INC <NUVL.O>: JEFFERIES INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $97
Reuters · 1d ago
Weekly Report: what happened at NUVL last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at NUVL last week (0401-0405)?
Weekly Report · 04/08 09:09
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
Ars Pharmaceuticals increased its stake in the biopharmaceutical company to 10,860,977 shares. Bain Capital Investors reduced its stake of the company to 2,697,267 shares. Vera Therapeutics and Takeda Pharmaceutical cut their stakes in the pharmaceutical company.
Barron‘s · 04/05 22:30
Nuvalent Price Target Raised to $110.00/Share From $69.00 by Leerink Partners
Dow Jones · 04/01 15:07
Nuvalent Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 04/01 15:07
Leerink Partners Upgrades Nuvalent to Outperform, Raises Price Target to $110
Benzinga · 04/01 14:57
NUVALENT INC <NUVL.O>: LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $69
Reuters · 04/01 10:06
Weekly Report: what happened at NUVL last week (0325-0329)?
Weekly Report · 04/01 09:09
Weekly Report: what happened at NUVL last week (0318-0322)?
Weekly Report · 03/25 09:09
Weekly Report: what happened at NUVL last week (0311-0315)?
Weekly Report · 03/18 09:09
Weekly Report: what happened at NUVL last week (0304-0308)?
Weekly Report · 03/11 09:09
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Nuvalent Is Maintained at Overweight by JP Morgan
Dow Jones · 03/06 16:08
S&P 500 Futures Climb In Premarket Trading; CrowdStrike Holdings, MicroStrategy Lead
U.S. Stock markets set to open in two hours. S&P 500 futures were up 0.37%, with futures for the Dow Jones Industrial Average rising 0.23%. Stocks in Asia were down overnight. Bitcoin rose 8.16% to $66,959.
Barron‘s · 03/06 12:31
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
Weekly Report: what happened at NUVL last week (0226-0301)?
Weekly Report · 03/04 09:09
More
Webull provides a variety of real-time NUVL stock news. You can receive the latest news about Nuvalent, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.